We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • Topics
  • Nutra-Q Directory
  • Magazine
  • e-Learning Tools
  • Advertise

Modern Medicine Network
  • Login
  • Register
Skip to main content
  • Login
  • Register
Menu
User
Home
  • Topics
  • Nutra-Q Directory
  • Magazine
  • e-Learning Tools
  • Advertise

SUBSCRIBE: eNewsletter | Magazine

First Evidence Sabinsa’s Curcumin Reduces Lipoprotein(a) Associated with Bad Cholesterol in Type 2 Diabetes

  • Photo © iStockphoto.com/Elzbieta Sekowska
  • Jennifer Prince
Aug 11, 2017
  • Heart Health, Blood Sugar, Herbs & Botanicals, Science

A new study, published in Complementary Therapies in Medicine,1 indicates that Sabinsa Corp.’s (East Windsor, NJ) proprietary Curcumin C3 Complex, in combination with its BioPerine black pepper extract bioavailability enhancer, may improve HDL cholesterol functionality and reduce non-HDL cholesterol in patients with type 2 diabetes. In addition, Sabinsa says, this clinical trial is the first curcuminoids research to demonstrate a reduction in lipoprotein(a), or Lp(a), which is a “protective armor” of LDL cholesterol.

The randomized, double-blind, placebo-controlled study was conducted over a period of twelve weeks. A total of 100 participants with type 2 diabetes completed the trial. The subjects were randomly divided into two groups, with 50 of the subjects given a combination of Curcumin C3 Complex (1000 mg/day) and BioPerine (10 mg/day), while 50 subjects were given a placebo. Researchers recorded measurements of subjects’ serum concentrations of lipids, including total cholesterol (TC), LDL cholesterol, HDL cholesterol, triglycerides, Lp(a), and non-HDL cholesterol at baseline and at the end of the trial. The study authors found that the group given the curcuminoid combination showed significant reductions in serum levels of total cholesterol, non-HDL cholesterol, and Lp(a) compared with the placebo group. Further, the group given the curcuminoids demonstrated increased levels of HDL cholesterol, with overall improved HDL functionality. The researchers say that they did not observe a significant difference in serum triglyceride or LDL-cholesterol between the active and placebo groups.

As the study authors point out, type 2 diabetes is a known risk factor for cardiovascular disease “and is associated with disturbed metabolism of lipids and lipoproteins.” Thus, the results of the study indicate that this combination of curcuminoids may help reduce the risk of cardiovascular events for subjects with type 2 diabetes.

“The overall conclusions in this study together with earlier studies on C3 Complex/BioPerine combination add to the body of science on its positive role in the health maintenance of diabetic subjects,” said founder of Sabinsa, Muhammed Majeed, PhD, in a press release. Majeed also contributed to the study.

Sabinsa says that, currently, the only drug interventions known to reduce Lp(a) are PCSK9 inhibitors, but notes that those are expensive and only available in injectable form. The absence of effective drug therapy for diabetes patients who may be more prone to cardiac events “further accentuates the importance of C3 Complex/BioPerine combo in such a scenario,” it says.

 

 

Also read: 

Curcumin C3 Complex May Reduce Oxidative Stress in Diabetes Patients

Sabinsa Becomes Initial Founding Board Member of Global Curcumin Association

Curcumin Plus EPA Omega-3 May Reduce Cancer-Related Muscle Loss?

References: 
  1. Panahi Y et al. “Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial.” Complementary Therapies in Medicine, vol. 33, (August 2017): 1-5

Related Articles

  • Mung Bean Protein Isolate May Improve Insulin Response, Reduce Fat Accumulation
  • Low-Glycemic Diet with Beneo’s Palatinose Supports Blood Sugar, Fat Burning, In New Study in Asian Subjects
  • Sabinsa Announces Reforestation Project to Ensure Supply of Indian Kino Tree
  • Botanical Extract Lowers Blood Glucose, Increases Levels of Insulin in Animal Study
  • Turmeric: Metabolic Health Powerhouse?

Fun Facts

Fun Fact!

Weekly Fun Facts about nutrition and ingredients, courtesy of Nutritional Outlook's editors

Current Issue

Nutritional Outlook Vol. 21, No 3
Apr 01, 2018 Vol 21 No 3
Digital Edition
Connect with Us
  • Twitter
  • Facebook
  • Google+
  • LinkedIn
  • RSS
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.